Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NuVasive Prepares Cervical Disc IDE Filing; Fusion Plate To Launch In July

This article was originally published in The Gray Sheet

Executive Summary

NuVasive intends to file an IDE application for a minimally-invasive cervical total artificial disc replacement within the next two weeks

You may also be interested in...



Medtronic’s Prestige Artificial Disc Will Be Put To Test At FDA Panel

Medtronic Sofamor Danek will be the first company to put an artificial cervical disc in front of an FDA advisory panel, the company confirmed Aug. 21

Medtronic’s Prestige Artificial Disc Will Be Put To Test At FDA Panel

Medtronic Sofamor Danek will be the first company to put an artificial cervical disc in front of an FDA advisory panel, the company confirmed Aug. 21

LDR Spine To Launch Study Of “Second-Generation” Cervical Disc

LDR Spine expects the first patient in its 593-patient, 20-site pivotal trial to be implanted with a Mobi-C artificial cervical spinal disc by mid-February

Related Content

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel